Pfizer PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NYSE | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Hamburg | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Santiago | USD | Delayed | ||
| Buenos Aires | ARS | Delayed | ||
| BM&FBovespa | BRL | Delayed | ||
| Vienna | EUR | Delayed | ||
| KASE | USD | Delayed | ||
| Colombia | COP | Delayed | ||
| Lima | USD | Delayed |
By Davit Kirakosyan Citi lowered the price target on McDonald’s (NYSE:MCD) to $277.00 from $279.00 while maintaining a Neutral rating. McDonald's reported its Q4 results...
By Sam Boughedda After a dip earlier in the session, AbbVie (NYSE:ABBV) shares are now slightly up on the day, holding steady, despite Amgen (NASDAQ:AMGN) announcing AMJEVITA, a...
2022. Earnings per share came in at $1.14, versus the expected $1.05.The reported revenue of $24.29 billion represents growth of 7.30% compared to the previous quarter, and growth...
Pfizer Stumbles As Vaccine Demand Expected To Slide Pfizer Inc shares slid as much as 3.5% in premarket trading (before bouncing back) after the company forecasted COVID-19 vaccine...
Pfizer came out with quarterly earnings of $1.14 per share.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
| Average | 54.300 (+22.962% Upside) |
| High | 75.000 |
| Low | 44.000 |
| Price | 44.160 |
| No. of Analysts | 20 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Neutral | Strong Sell | Neutral |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 11.00 | 11.18 | 10.82 | 0.00 | 0.00% | 93.30K | Aquis Exchange | |||
| 50.50 | 50.50 | 50.50 | +0.50 | +1.00% | 20.16K | London | |||
| 10,494.00 | 10,626.00 | 10,472.00 | -96.0 | -0.91% | 340.29K | London | |||
| 160.93 | 161.60 | 160.00 | +1.70 | +1.07% | 1.90M | London | |||
| 91.02 | 92.10 | 90.05 | -2.13 | -2.29% | 34.81M | London | |||
| 658.60 | 670.20 | 646.80 | +12.60 | +1.95% | 304.11K | London | |||
| 856.00 | 857.60 | 844.20 | -0.80 | -0.09% | 1.39M | London | |||
| 203.40 | 203.90 | 202.60 | +1.50 | +0.74% | 784.34K | London | |||
| 93.40 | 94.20 | 93.20 | -0.50 | -0.53% | 329.12K | London | |||
| 98.34 | 98.70 | 97.00 | +0.30 | +0.31% | 153.27K | London | |||
| 1.256 | 1.256 | 1.256 | +0.0050 | +0.39% | 7.17M | London | |||
| 714.40 | 720.00 | 710.00 | +6.00 | +0.85% | 437.58K | London | |||
| 183.36 | 190.00 | 178.00 | -4.40 | -2.36% | 114.94K | London | |||
| 130.40 | 130.60 | 130.00 | -0.20 | -0.15% | 713.52K | London | |||
| 589.80 | 594.20 | 585.80 | +3.00 | +0.51% | 1.15M | London |